Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis

Liver fibrosis, a leading cause of cirrhosis and liver cancer, is the advanced stage of non-alcoholic fatty liver disease (NAFLD). There is an urgent need for antifibrotic therapeutics targeting hepatic fibrosis as no treatments are currently approved.1 Recently, Jiwoon et  al. developed a human pluripotent stem cell-derived multicellular liver culture and revealed that the IL-6/STAT3 signaling pathway may dictate hepatic stellate cell (HSC) activation and NAFLD progression.2 A mouse model study by Dai-Min et al.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research